Avid Bioservices Inc (CDMO)

[cheynew]

Schedule A supporting CSM's proposal:

CSM
Clinical Supplies Management
Trista w/2 Backstrom
[e-mail]
Allison w/2 Coatsworth
[e-mail]
Marcus w/2 Rondestvedt
[e-mail]
Sarah w/2 Rosenau
[e-mail]
Angela w/2 Nordstrom
[e-mail]
Brenda w/2 Undem
[e-mail]
Cathy w/2 Newman
[e-mail]
Sherri w/2 Blanchard
[e-mail]
Robert w/2 Albanese
Bob w/2 Albanese
[e-mail]
Laura w/2 Lehan
[e-mail]
Jeanette w/2 Bleecker
[e-mail]
Gerald w/2 Finken
[e-mail]
Angela w/2 Buchanan

EXHIBIT A
[e-mail]
Angela w/2 Humrich
[e-mail]
Don w/2 Berg
[e-mail]
Jennifer w/2 Lauinger
[e-mail]
RTSM
Perceptive Informatics
Peter w/2 Jehlen
[e-mail]
Jawahar w/2 Varma
[e-mail]
Smita w/2 Pandit
smita.pandit@perceptive .com
Vasanth w/2 Rachamalla
[e-mail]
Lauz w/2 Tamieka
[e-mail]
Scott w/2 Katherine
[e-mail]
Barbara w/2 Chandler
[e-mail]
Synteract Inc.
Marie w/2 Tan
[e-mail]
Ricky w/2 Tolentino
[e-mail]

EXHIBIT A
Eileen w/2 Graves
[e-mail]
Mark w/2 Mortier
[e-mail]
Daniel w/2 Haight
[e-mail]
Jacci w/2 Patterson
[e-mail]
Elaine w/2 Law
[e-mail]
Laura w/2 Hopper
[e-mail]
Carol w/2 Wong
[e-mail]
Ed w/2 Lombardi
[e-mail]
Avid Bioservices
PRA International
Ulrich w/2 Hackenberg
[e-mail]
Isabel w/2 Hart
[e-mail]
Carolyn w/2 Stephens
[e-mail]
Margie w/2 Holmes
[e-mail]
ICON Central Laboratories
ICON Clinical Laboratories

EXHIBIT A
Teshaye w/2 Smith
[e-mail]
Zareh w/2 Ghokassain
[e-mail]
My w/2 Nguyen
[e-mail]
[e-mail]
[e-mail]
Jason w/2 Ciangetti
[e-mail]
Jennifer w/2 Coppins
[e-mail]
Michael w/2 Helmich
ICON Development Solutions
Stephen w/2 Bradley
[e-mail]
Steve w/2 DeMattos
Independent Data Monitoring Committee
PPHM w/2 0902
Protocol w/2 0902
Bavituximab and Phase w/2 II
Bavituximab and Phase w/2 2
Bavituximab and Phase w/2 IIIBavituximab and Phase w/2 w/2 III
PPHM and 0902 and Protocol
“Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Bavituximab Plus
Docetaxel in Patients with Previously Treated Locally Advanced or Metatastic NonSquamous
Non-Small-Cell Lung Cancer”
Master Services Agreement
Case 8:12-cv-01608-JGB-AN Document 70-2 Filed 02/11/15 Page 5 of 15 Page ID #:129815
EXHIBIT A
Docetaxel
@fda.gov
FDA
Food & Drug Administration
Bavituximab Regulatory File
Bavituximab Fast Track
Bavituximab Trial Design
Bavituximab end-of-Phase II meeting
Bavituximab end-of-Phase 2 meeting
EOP2
Bavituximab Registration Trial
PPHM 0902 Data
Sunrise
MSA
Kick-off Meeting
Management Team Meeting
Management Team Meeting Minutes
PPHM 0902 Minutes
Bavituximab Minutes
Investigator’s Brochure
Investigator’s Meeting
Investigator’s Meeting Minutes
0902 Randomization
0902 PLR
0902 Packaging and Labeling Requirements
AbbVie, Inc.
Abbott
Standard Operating Procedures
Case 8:12-cv-01608-JGB-AN Document 70-2 Filed 02/11/15 Page 6 of 15 Page ID #:129916
EXHIBIT A
SOP
Independent Safety Monitoring Committee
ISMC
Bavituximab Institutional Review Board
Bavituximab IRB
Corrective and Preventive Actions (CAPA)
Double blind
Second-Line Non-Small Cell
Bavituximab interim data
treatment code assignments
Bavituximab news release
Bavituximab platform
Phase II itemization of costs
0902 budget
0902 costs
Phase III itemization of costs
Bavituximab registration package
1202 budget
Peregrine market capitalization
Bavituximab Investigator’s Brochure
Investment partners
Peregrine sponsored Bavituximab speeches, abstracts, poster boards, press
conferences, publications, interviews, conference calls, PowerPoint presentations,
webinars
Phase II Trial publications
Bavituximab articles
Bavituximab posters/abstracts
http://www.sunrisetrial.com
Case 8:12-cv-01608-JGB-AN Document 70-2 Filed 02/11/15 Page 7 of 15 Page ID #:130017
EXHIBIT A
Bavituximab meeting minutes
Peregrine earnings calls (for the years 2012 – 2014) (including scripts, outlines,
memoranda, talking points, syllabi, digests and summaries)
University of Texas Southwestern Medical Center
University of California, Irvine
Human Genome Sciences, Inc.
Oxford Finance LLC (before September 24, 2012 regarding the results of the Phase II
Trial)
Oxford Finance LLC (regarding the alleged coding and labeling discrepancies or other
errors in the Phase II Trial)
Silicon Valley Bank (before September 24, 2012 regarding the results of the Phase II
Trial)
Silicon Valley Bank (regarding the alleged coding and labeling discrepancies or other
errors in the Phase II Trial)
MidCap Financial SBIC, LP (before September 24, 2012 regarding the results of the
Phase II Trial)
MidCap Financial SBIC, LP (regarding the alleged coding and labeling discrepancies or
other errors in the Phase II Trial)
Bavituximab Pharmacokinetic data
Bavituximab audit
A.J. Leyco performance review/evaluation/assessment/accreditations/training/education
Janet Nuttall performance review/evaluation/assessment/accreditations/training/education
Joseph Shan performance review/evaluation/assessment/accreditations/training/education
Jeffrey Masten performance
review/evaluation/assessment/accreditations/training/education
Bavituximab randomized kit
Bavituximab open label kit
Site monitoring report

EXHIBIT A
Site visit
DMC
Data Monitoring Committee
ClinPhone
PRS
Project Requirements Specification
Fundamentals
Master Batch Records
MBR
Distribution Processing Protocol
eCRF
Case Report Form
Unblinding Services Processing Protocol
PPHM 1202
Blinding
Treatment Arm
Project Communications Plan
IVRS
IWRS
IWR
P value
Registration study
PK
Pharmacokinetic
NSCLC
Sub-study
1 mg/kg
3 mg/kg

EXHIBIT A
HR
Hazard ratio
Confirmatory
Median overall survival
Overall survival
MOS
OS
Drug coding
For cause audit
QC²
Quality Compliance and Consulting
Discrepancies
Treatment group assignment
A280
Coomassie Plus BradfordTM Assay
ECLA
HACA
EOP2
Term sheet
Masking
Randomization Schedule Specification Form
Relabeling
Reconciliation
Study Summary Report
Site Summary Report
ClinPhone User Account Report
Unblinded Study Summary Report
Site visit

EXHIBIT A
ORR
Overall response rate
PFS
Progression Free Survival
Statistical power assumption
Project Communication Plan
Inventory Tracking
ECL
electrochemiluminescence
University of Utah
South Bay Hematology
Nebraska Hematology
Coastal Bend
Georgia Cancer
The Christ Hospital
Tennessee Oncology
Florida Cancer Specialists
Hanover Medical Specialists
Northwest Georgia Oncology
Frederick Memorial Hospital
Pennsylvania State Hershey
Ironwood Cancer
Parkland Health
Mary Crowley
Bangalore Institute of Oncology
Ruby Hall Clinic
BiBi General Hospital
Kodlikeri Memorial

EXHIBIT A
All India Institute
SMS Medical College
Shatabdi Superspecialty Hospital
Medulla-Chemotherapy
Kiev City Oncology
State Budget Institution of Healthcare Chelyabinsk
Saint-Petersburg State Medical University
Patient Identification Numbers:
048003
048004
050002
053003
055001
056006
056011
057005
057008
057011
057012
057017
057019
066003
079005
079006
079009
510003
510004
514003

EXHIBIT A
529002
529011
530004
532004
532013
532019
532021
532025
533001
533002
701002
713003
715001
715004
718001
718002
718003
719001
719003
723001
005001
050003
052002
056005
056012
056013
057007
057010

EXHIBIT A
057013
057014
059002
060001
062001
072003
072005
079007
079008
079010
080001
086001
514005
514006
529003
530003
531003
532012
532014
532015
532020
533003
701001
701003
701005
701006
701007
701008

EXHIBIT A
715003
715005
715008
719002
Case 8:12-cv-01608-JG